Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 8/20 | 0.35 |
| ▸ | PPID | Q08752 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL4374692 | 0.83 | NLRP3 (0.36) | NLRP3MARS1PPIDMEN1KMT2A | |
| SCHEMBL2998422 | 0.77 | NLRP3 (0.46) | NLRP3KDM4EALDH1A1HPGDGLA | |
| SCHEMBL2998076 | 0.72 | NLRP3 (0.48) | NLRP3KDM4EALDH1A1HPGDGAA | |
| SCHEMBL3000425 | 0.71 | NLRP3 (0.43) | NLRP3KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL12229225 | 0.67 | LMNA (0.43) | ALDH1A1GAAMARS1MEN1KMT2A | |
| SCHEMBL12229268 | 0.67 | LMNA (0.43) | ALDH1A1GAAMARS1MEN1KMT2A | |
| SCHEMBL13038941 | 0.66 | NLRP3 (0.42) | NLRP3KDM4EALDH1A1GAAMAPT | |
| SCHEMBL19283982 | 0.65 | LMNA (0.49) | GAAMAPTHSD17B10MARS1LMNA | |
| SCHEMBL5443843 | 0.65 | METAP2 (0.53) | MARS1PPIDMETAP2METAP1 | |
| SCHEMBL113611 | 0.65 | METAP2 (0.53) | MARS1PPIDMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | NLRP3 210/4885KDM4E 832/4885ALDH1A1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.